Increased FP-CIT binding in the LC area
The present study provides
in vivo evidence of higher baseline catecholamine transporter binding in the LC region in a large and homogeneous cohort of subjects with early PD. Our findings are consistent with an up-regulation of noradrenaline reuptake in the LC area, which is well compatible with enhanced noradrenaline release [
19,
20].
Our results are derived from the analysis of the binding of FP-CIT, a
123I-labeled cocaine derivative with high affinity for dopamine (DAT; K
D = 2nM) and a lesser affinity towards noradrenaline transporter (NET; K
D = 140 nM) [
14]. Despite the higher affinity of FP-CIT for DATs, it is unlikely that the higher binding observed in the LC area is due to an enhanced dopaminergic, rather than noradrenergic, transporter for two main reasons: (i) in LC, DAT represent a minor and inconsistent component of the midbrain-derived dopaminergic terminals which degenerates in PD, along with other dopaminergic projections, [
4] and (ii) in the LC a major NET component is synthesized in the cell body of pigmented neurons and exposed on their membrane to be transferred toward axonal terminals, [
20] with a less consistent NET component localized on terminal projections arising from more caudal noradrenergic cell groups [
21].
In PD, reduced dopamine release from nigro-striatal projections results in loss and adaptive down-regulation of DAT binding sites in the striatal region [
22]. In line with this notion, and in agreement with studies in
de novo and early PD, where 40 to 60% of nigral dopaminergic neurons are lost, [
15,
23] we found a significantly reduced FP-CIT binding in the caudate and putamen of PD patients. In contrast to the striatal compartment, analysis of FP-CIT labeling in the upper brainstem revealed significantly increased binding in a pontine area adjacent to the floor of the fourth ventricle and extending into the midbrain to the level of the inferior colliculi. This area corresponds topographically to the LC coordinates identified by other studies including those employing neuromelanin-sensitive MRI methods [
6,
17,
24,
25]. In addition, the LC is the sole structure in the posterior rostral pons housing monoamine transporters [
1], thus further supporting our claim of anatomical targeting of the LC.
Only two prior studies with PET have specifically investigated the LC in PD patients. A first, [
24] reported a reduced
18F-dopa intake in patients with advanced PD when compared to patients at an early stage of the disease. Because
18F-dopa intake is more specifically related to dopaminergic neurotransmission, this study does not provide information on noradrenergic functioning of LC. In a second study, [
6] PD subjects with depression showed a reduced binding of [
11C]RTI-32, a marker of both DAT and NET, when compared to non-depressed patients. Interestingly, the noradrenergic activity of early non-depressed PD patients was within normal range in most patients and enhanced in few of them. In line with these findings, and having enrolled a larger and more selected cohort of subjects, we were able to reveal a significantly higher LC activity at an early stage of PD for the first time.
An acute effect of drugs on FP-CIT binding values appears unlikely since SPECT was performed after overnight withdrawal of anti-parkinsonian drugs. In addition, in animal studies, systemic administration of D
2/D
3 receptor agonists, such as pramipexole or apomorphine, showed little or no effect on the firing rate of LC-NA neurons [
26]. Finally, a persistent treatment with dopaminergic drugs will eventually down-regulate, rather than up-regulate, the surface expression of DAT and NET through internalization of the transporters [
27,
28]. Accordingly, the average FP-CIT binding values in the LC remained enhanced when data were L-Dopa weighted for equivalent daily dose and L-Dopa daily dose.
In vivoversus anatomopathological studies
Enhanced noradrenergic binding, and possibly activity, in PD might be considered at odds with neuropathological findings, where frank neuronal degeneration has been recognized within LC, based on detection of specific cellular markers. Indeed, morphologic hallmarks of sporadic PD (Lewy bodies and dystrophic neurites containing pathologic α-synuclein) may appear initially in the lower brainstem [
2].
However, Lewy pathology can correlate poorly with neuronal loss in specific areas, thus its validity in predicting neuronal disintegration is questionable [
29]. In fact, noradrenergic neurons in the LC are relatively preserved in early PD and do not exhibit the same intracellular changes as in the substantia nigra [
30].
Accordingly, neuromelanin-sensitive imaging methods
in vivo, [
25] as well as anatomopathological studies suggested that the loss of NA neurons in PD may be confined to the larger, pigmented cells localized in the caudal part of the nucleus, whereas small unpigmented cells are increased in number, as if derived from shrinkage of larger neurons [
31].
However, available information on the LC, so far derived from anatomopathological studies in subjects with PD, is poorly comparable with our findings. In particular, the limited number of PD subjects investigated and the lack of clinical information (e.g. disease duration and the presence of depression or cognitive impairment) of patients in anatomopathological studies prevent a direct comparison between these studies and our results [
31,
32].
Implications of enhanced LC-NA functioning in PD at an early stage
Based on anatomical and histochemical data, along with neuropharmacological evidence, higher activity of the LC in PD may suggest: (i) in the striatum, noradrenaline plays a compensatory role cross targeting dopaminergic receptors (synaptic action); while (ii) in the substantia nigra, noradrenaline has a neuroprotective bolstering dopaminergic cells (extra-synaptic paracrine action).
As for the compensatory role, there is no absolute specificity for catecholaminergic substrate-receptor interactions, implying that one catecholamine can cross-talk with the pharmacologically defined receptors or transporters belonging to other catecholamines. Indeed, noradrenaline binds to pharmacologically defined dopaminergic receptors [
11,
33,
34]. Therefore, enhanced noradrenaline release may be able to partially compensate a dopaminergic innervation loss due to degeneration of the substantia nigra.
With reference to a putative neuroprotective activity, noradrenaline suppresses pro-inflammatory and elevates anti-inflammatory molecules [
35] and has the ability to scavenge superoxide and reactive oxygen species, which are thought to contribute to cellular damage and dopaminergic cell death [
36]. Furthermore, the tottering mouse, which has noradrenergic hyperinnervation and increased levels of noradrenaline throughout the forebrain, appears to be protected from MPTP toxicity [
37] while MPTP-induced damage to nigrostriatal dopaminergic neurons was potentiated by pretreatment with DSP-4, a selective LC neurotoxin [
38]. Therefore, we speculate that enhanced LC-NA may be regarded as an endogenous paracrine agent promoting dopaminergic neuron survival [
39,
40]. This hypothesis would predict that degeneration of LC noradrenergic neurons in later stages of the disease might accelerate degeneration of substantia nigra dopaminergic neurons. The negative correlation between FP-CIT binding in the striatum and LC area is consistent with the above considerations of LC-NA compensatory and protective activity.